Related Experiment Video
Updated: May 5, 2026
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
Allosteric Anti-KLK4 Antibody Development for Targeted Anti-cancer Effects in Ovarian Carcinoma
Nikolaos A Afratis1, Blake T Riley2, Peter G Chandler2
1Department of Immunology and Regenerative Biology, Weizmann Institute of Science, 234 Herzl Street, Rehovot 7610001, Israel; Department of Agricultural Development, Agri-food & Management of Natural Resources, National and Kapodistrian University of Athens, Evripos Campus, Psachna 34400 Evia, Greece.
Abstract:
Kallikrein-related peptidases (KLKs) have garnered significant interest in the field of biomedical research due to their diverse roles in various physiological and pathological processes. However, the structurally conserved active site of the KLK family presents challenges for the development of specific inhibitors. Given the pro-tumorigenic roles KLKs play in various cancers, identifying new avenues for specific inhibition is therefore vital. Here, we introduce a novel approach to target a distinct KLK4 sequence by a unique immunization approach for monoclonal antibody generation, targeting loop 3, a region of high sequence and structural diversity as a candidate for allosteric control of KLK4 activity. Immunisation produced an antibody capable of interacting with both KLK4 and loop 3 with high affinity, which inhibited KLK4 proteolytic activity, and hindered proliferation and migration in ovarian cancer cell lines. Encouragingly, its potential application extends to preclinical models characterized by KLK4 overexpression. Our findings underscore the promise of this novel approach to addressing the challenges of specifically inhibiting ubiquitous serine proteases, with particular relevance to targeting KLK4, a protease instrumental in the progression of ovarian carcinoma and other cancer types.
Insights
Researchers developed a novel antibody targeting kallikrein-related peptidase 4 (KLK4) to inhibit cancer progression. This antibody effectively reduced ovarian cancer cell proliferation and migration, offering a promising new therapeutic strategy.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Kallikrein-related peptidases (KLKs) are implicated in diverse physiological and pathological processes, including cancer.
- The conserved active site of KLKs poses a challenge for developing specific inhibitors.
- KLKs play pro-tumorigenic roles in various cancers, necessitating novel inhibition strategies.
Purpose of the Study:
- To develop a novel approach for specific inhibition of KLK4, a key protease in ovarian carcinoma progression.
- To generate monoclonal antibodies targeting a distinct KLK4 sequence for allosteric control.
Main Methods:
- A unique immunization approach was employed for monoclonal antibody generation.
- The antibody was designed to target loop 3 of KLK4, a region of high sequence and structural diversity.
- The antibody's efficacy was evaluated in vitro using ovarian cancer cell lines and in vivo in preclinical models.
Main Results:
- An antibody was generated that binds KLK4 and loop 3 with high affinity.
- The antibody successfully inhibited KLK4 proteolytic activity.
- The antibody hindered proliferation and migration in ovarian cancer cell lines and showed potential in preclinical models with KLK4 overexpression.
Conclusions:
- This novel antibody approach offers a promising strategy for the specific inhibition of KLK4.
- Targeting loop 3 provides a viable method for allosteric control of KLK4 activity.
- The findings highlight the potential of this approach for treating ovarian carcinoma and other KLK4-associated cancers.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...